HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

NOW APPROVED For moderate to severe rheumatoid arthritis (RA) in adult MTX-IR patients1

Older woman in a harnass, ziplining
Durable remission even without MTX Durable remission even without MTX Durable remission even without MTX

Achieved DAS28-CRP<2.6 (ranked secondary endpoint) at Week 12 or 14, with remission rates up to ~1 year. Remission was also evaluated using additional measures.1-6

C-reactive protein (CRP) variant; DAS28-CRP=Disease Activity Score, 28 Joints; IR=intolerance or inadequate response; MTX=methotrexate

Clinical Trial Overview

*P ≤ 0.001 RINVOQ vs Placebo2

SELECT-COMPARE (Study RA-IV) Study Design Intro:2
48-week, randomized, double-blind,
active comparator-controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at week 12 vs. placebo. Prespecified blinded rescue protocol occurred at weeks 14, 18, 22, or 26.

*P ≤ 0.001 RINVOQ vs MTX1

SELECT-MONOTHERAPY (Study RA-II) Study Design Intro:1,5
14-week, randomized, double-blind, active comparator-controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at week 14.

Remission data across measures at week 12 or 14 Remission data across measures at week 12 or 14 Remission data across measures at week 12 or 14

SELECT-COMPARE:
Clinical Remission Data (Week 12)

RINVOQ + MTX vs Placebo + MTX

SELECT-MONOTHERAPY:
Clinical Remission Data (Week 14)

RINVOQ vs MTX

SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data

Switching from MTX to UPADAC monotherapy: See the results

 

Professor Paul Emery, Rheumatologist reviews SELECT-MONOTHERAPY, a phase 3 trial comparing MTX patients who switched to UPADAC vs those who remained on MTX.

Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX

SELECT-COMPARE:
DAS28-CRP<2.6
RINVOQ + MTX vs Placebo + MTX at Week 12

SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12 SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12 SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis were not controlled for multiplicity; p-values were obtained through nominal statistical testing.

Treatment groups are by initial randomization. Observations after rescue were handled using NRI (weeks 14-22) and LOCF (week 26).

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Durable remission up to 1 year: RINVOQ vs MTX Durable remission up to 1 year: RINVOQ vs MTX Durable remission up to 1 year: RINVOQ vs MTX

SELECT-MONOTHERAPY:
DAS28-CRP<2.6
RINVOQ vs MTX at Week 14

SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14 SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14 SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14

Treatment groups are by initial randomization.
Starting at Week 26, initiation of or change in csDMARDs was allowed for patients who did not achieve CDAI≤10.

Chart legend

See the impact of RINVOQ on radiographic inhibition, with and without MTX

Get a closer look at data from Weeks 24 or 26,
and Week 48.

RINVOQ is not indicated in MTX-naïve patients

Discover how RINVOQ Complete can provide exceptional access and product support

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking